Smith & Nephew to buy privately-held Healthpoint for $782 million

UK healthcare firm Smith & Nephew today agreed to buy privately-held Healthpoint for $782 million in cash in order to expand in the fastest growing area of advanced wound management.

Fort Worth, Texas-based Healthpoint focuses on the development and commercialisation of novel, cost-effective bioactive solutions for debridement, dermal repair and regeneration.

Its main product is Collagenase Santyl Ointment, an enzymatic debrider for dermal ulcers and burns. Healthpoint's other products are Oasis a cellular skin substitute for venous leg ulcers and diabetic foot ulcers, and Regranex, a growth factor for treating diabetic foot ulcers.

Healthpoint has approximately 460 employees, including an established sales force of 215.

The company generated revenues of $151 million in 2011 and is forecast to deliver around $190 million in 2012.

Olivier Bohuon, CEO of Smith & Nephew, said, ''The acquisition of Healthpoint is an important step for Smith & Nephew.  Strategically, it reinforces our Advanced Wound Management division by giving us a strong position in the fast growing area of bioactive wound care treatment.''